

# ASX Announcement

## 1 May 2018



## Change to senior management team

Departure of Chief Operating Officer

The cognitive science company, Cogstate Ltd (ASX.CGS) announced today that George Hunnewell has concluded his role as Chief Operating Officer of Cogstate and President of the company's Clinical Trials division.

Cogstate does not plan to replace the COO and President position. Instead, Cogstate CEO Brad O'Connor will return to a more active role in the day-to-day running of Cogstate's core clinical trials business, which is experiencing continued growth in its existing and new market segments.

### For further information contact:

Brad O'Connor  
Cogstate Chief Executive Officer  
+61 3 9664 1300 or 0411 888 347  
[boconnor@cogstate.com](mailto:boconnor@cogstate.com)

Kyahn Williamson  
WE Buchan  
0401 018 828  
[kwilliamson@we-buchan.com](mailto:kwilliamson@we-buchan.com)

---

### About Cogstate

Cogstate Ltd (ASX:CGS) is a leading science and technology solutions provider dedicated to optimizing the measurement of cognition in clinical trials, academic research and healthcare. Cogstate provides enabling technologies and professional services for higher quality neuropsychological assessments and is a pioneer in commercializing rapid, reliable and highly sensitive computerized cognitive tests. Cogstate customers include the world's leading biopharmaceutical companies; elite sporting organizations and military; physicians and patients; renowned academic institutions and public-private partnerships. For more information, please visit [www.cogstate.com](http://www.cogstate.com).